A Single-center, Phase II Clinical Study of Sacituzumab Govitecan Combined With Toripalimab as Neoadjuvant Therapy for Resectable Stage II-IIIB NSCLC
Latest Information Update: 07 Apr 2026
At a glance
- Drugs Sacituzumab govitecan (Primary) ; Toripalimab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms TianjinCIH
Most Recent Events
- 04 Mar 2026 New trial record